

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information

Product ID	P1202		Ö ÖH	
CAS No.	391210-10-9		O OH	
Chemical Name		F F		
Synonym	PD0325901			
			I	
Formula	C ₁₆ H ₁₄ F ₃ IN ₂ O ₄			
Formula Formula Wt.				
	482.19	Bulk quanit	tites available upon requ	iest
Formula Wt.	482.19 >98%			iest
Formula Wt. Melting Point Purity	482.19 ≥98% Soluble in DMSO at 12 mg/mL; soluble in ethanol at 6.3 mg/mL with slight warming;	<i>Bulk quanit</i> Product ID P1202 P1202 P1202 P1202	tites available upon requ Size 5 mg 25 mg 100 mg	lest
Formula Wt. Melting Point Purity	482.19 ≥98% Soluble in DMSO at 12 mg/mL; soluble in ethanol at 6.3 mg/mL with slight warming; very poorly soluble in water	Product ID P1202 P1202	Size 5 mg 25 mg	lest

Description PD-325901 is an anticancer chemotherapeutic MEK1/2 and Raf inhibitor that is particularly effective against cancers harboring B-Raf or Ras mutations such as V600E. PD-325901 decreases levels of phosphorylated ERK1/2, cyclin D1, and thymidine kinase 1. PD-325901 also induces cell cycle arrest at the G0/G1 phase, inhibiting proliferation in thyroid cancer cell lines. In vivo, this compound decreases tumor growth and size. Additionally, PD-325901 displays antiviral benefit, synergizing with other treatments in cellular models of influenza infection.

References Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 2013 May;98(2):319-24. PMID: 23523553.

Leyton J, Smith G, Lees M, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther. 2008 Sep;7(9):3112-21. PMID: 18790789.

Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008 Aug;18(8):853-64. PMID: 18651802.

Brown AP, Carlson TC, Loi CM, et al. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007 Apr;59(5):671-9. PMID: 16944149.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.